Discovery Cohort
We conducted a prospective, open label, randomized cross-over study to
assess the effects of antiplatelet therapy (non-enteric coated aspirin
81 mg/day, aspirin 325 mg/day, and ticagrelor 90 mg twice daily) on
platelet function and gene expression as previously described.[19]
The results of aspirin exposure are presented here. The Supplemental
Methods provides more details of inclusion/exclusion criteria. The Duke
Institutional Review Board approved the study protocol.